Disease-Modifying Effects of Edasalonexent in Duchenne Muscular Dystrophy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neuromuscular Disorders
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Disease-Modifying Effects of Edasalonexent, an NF-κB Inhibitor, in Young Boys With Duchenne Muscular Dystrophy: Results of the MoveDMD Phase 2 and Open Label Extension Trial
Neuromuscul. Disord. 2021 Feb 04;[EPub Ahead of Print], RS Finkel, E Finanger, K Vandenborne, HL Sweeney, G Tennekoon, PB Shieh, R Willcocks, G Walter, WD Rooney, SC Forbes, WT Triplett, SW Yum, M Mancini, J MacDougall, A Fretzen, P Bista, A Nichols, JM DonovanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.